Mercer Global Advisors
ELEV

Mercer Global Advisors’s Elevation Oncology ELEV Stock Holding History

Mercer Global Advisors’s Portfolio ELEV Stock Details ELEV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-10,025
Closed -$5.62K – 2154
2024
Q3 		$5.62K Sell
10,025
-475
-5% -$704 ﹤0.01% 1949
2024
Q2 		$28.4K Buy
+10,500
New +$39.5K ﹤0.01% 1935

Other funds holding ELEV

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Mercer Global Advisors's ELEV Position: Q4 2024 in Review

Mercer Global Advisors sold out of Elevation Oncology (ELEV) in Q4 2024, closing a stake of 10,025 shares — an estimated $5.62K sold.

Mercer Global Advisors first reported a position in ELEV in Q2 2024 and held it in 2 quarters. The position peaked at $28.4K in Q2 2024. 71 funds tracked by Wall St. Rank hold ELEV as of Q4 2024.

  • Mercer Global Advisors reported no remaining Elevation Oncology position as of Q4 2024 after selling out during the quarter.
  • Mercer Global Advisors sold 10,025 Elevation Oncology shares in Q4 2024, an estimated $5.62K.
  • Mercer Global Advisors first reported a position in Elevation Oncology in Q2 2024 and held it in 2 quarters.
  • Mercer Global Advisors's Elevation Oncology position peaked at $28.4K in Q2 2024.
  • 71 funds tracked by Wall St. Rank held Elevation Oncology as of Q4 2024.

Based on Mercer Global Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.